Some providers prescribe Ozempic or Rybelsus off-label (something not approved by the FDA) for weight loss and to reduce the risk of weight-related health complications
Specific genetic variants in the GLP-1 receptor gene and related metabolic pathways determine how your body processes and responds to these medications
The future of beauty is inside out, and glutathione is at the forefront
An overview of etiology and treatment PubMed pubmed.ncbi.nlm.nih.gov [5] Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis ScienceDirect [6] Systematic review and meta-analysis of comprehensive behavioral family lifestyle interventions addressing pediatric obesity PubMed pubmed.ncbi.nlm.nih.gov [7] Semaglutide 2.4-mg injection as a novel approach for chronic weight management PubMed pubmed.ncbi.nlm.nih.gov [8] Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis ScienceDirect [9] Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis ScienceDirect [10] Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg PubMed pubmed.ncbi.nlm.nih.gov [11] Role of GLP-1 Receptor Agonists in Pediatric Obesity: Benefits, Risks, and Approaches to Patient Selection PubMed pubmed.ncbi.nlm.nih.gov [12] Role of GLP-1 Receptor Agonists in Pediatric Obesity: Benefits, Risks, and Approaches to Patient Selection PubMed pubmed.ncbi.nlm.nih.gov [13] The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Adolescents Without Diabetes Mellitus: A Systematic Review and Meta-Analysis PubMed pubmed.ncbi.nlm.nih.gov [14] Efficacy of liraglutide in pediatric obesity: A review of clinical trial data ScienceDirect [15] The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis ScienceDirect [16] The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis ScienceDirect [17] The effect of GLP-1RAs on mental health and psychotropics-induced metabolic disorders: A systematic review ScienceDirect [18] Metabolic outcomes and safety of GLP-1 receptor agonists in children and adolescents with obesity: A systematic review and meta-analysis PubMed pubmed.ncbi.nlm.nih.gov [19] Adverse Effects of GLP-1 Receptor Agonists PubMed pubmed.ncbi.nlm.nih.gov [20] Use of glucagon-like-peptide 1 receptor agonist in the treatment of childhood obesity PubMed pubmed.ncbi.nlm.nih.gov [21] Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks ScienceDirect [22] Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks ScienceDirect [23] Role of GLP-1 Receptor Agonists in Pediatric Obesity: Benefits, Risks, and Approaches to Patient Selection PubMed pubmed.ncbi.nlm.nih.gov [24] Use of glucagon-like-peptide 1 receptor agonist in the treatment of childhood obesity PubMed pubmed.ncbi.nlm.nih.gov [25] Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis ScienceDirect [26] Semaglutide for the treatment of obesity PubMed pubmed.ncbi.nlm.nih.gov [27] Metabolic outcomes and safety of GLP-1 receptor agonists in children and adolescents with obesity: A systematic review and meta-analysis PubMed pubmed.ncbi.nlm.nih.gov [28] The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis ScienceDirect [29] Adverse Effects of GLP-1 Receptor Agonists PubMed pubmed.ncbi.nlm.nih.gov [30] GLP-1 Receptor Agonists for Treatment of Pediatric Obesity: Behavioral Health Considerations PubMed pubmed.ncbi.nlm.nih.gov [31] Semaglutide for the treatment of obesity PubMed pubmed.ncbi.nlm.nih.gov [32] Semaglutide 2.4-mg injection as a novel approach for chronic weight management PubMed pubmed.ncbi.nlm.nih.gov [33] Systematic review and meta-analysis of comprehensive behavioral family lifestyle interventions addressing pediatric obesity PubMed pubmed.ncbi.nlm.nih.gov [34] Understanding recent trends in childhood obesity in the United States PubMed pubmed.ncbi.nlm.nih.gov [35] Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis ScienceDirect [36] A cost comparison of GLP-1 receptor agonists and bariatric surgery: what is the break even point
After removing 240 duplicate entries, 1,330 unique records remained for screening
The proportion of patients achieving the ADA-recommended target of HbA1c below 7% was also substantially higher with Rybelsus: in PIONEER 7, 58% of oral semaglutide patients reached target compared with just 25% on sitagliptin meaning Rybelsus helped approximately 1.7 times more patients achieve A1C control
)
